The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; FORMA Therapeutics; Janssen; Merck; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Taro Iguchi
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Astellas Pharma; Bayer Yakuhin; Janssen; Sanofi
Research Funding - Astellas Pharma; Bayer Yakuhin
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Plexxikon (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Jeffrey Holzbeierlein
Consulting or Advisory Role - Basilea
Research Funding - MDxHealth (Inst)
(OPTIONAL) Uncompensated Relationships - Astellas Medivation
 
Arnauld Villers
Research Funding - Astellas Pharma (Inst); IPSEN (Inst); Janssen Oncology (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Antonio Alcaraz
Consulting or Advisory Role - Astellas Pharma
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen; Olympus
 
Boris Alexeev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Eisai; ICON Clinical Research; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar
 
Francisco Gomez-Veiga
Research Funding - Abbvie; Astellas Pharma; AstraZeneca
 
Brad Rosbrook
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Fabian Zohren
Employment - Pfizer
Stock and Other Ownership Interests - AlloVir; AlloVir (I); Pfizer; Pfizer (I)
 
Shunsuke Yamada
Employment - Astellas Pharma
 
Gabriel P. Haas
Employment - Astellas Pharma
 
Arnulf Stenzl
Consulting or Advisory Role - Alere; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; Roche; Steba Biotech; Synergo
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bayer (Inst); Cepheid (Inst); GenomeDx (Inst); immatics (Inst); Janssen; Johnson & Johnson (Inst); Karl Storz (Inst); Medivation; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - 2018/6579 Gene-expression signature for subtype and prognostic prediction of renal cell carcinoma; AT00/0001:C-Trap, implantable device to treat urinary incontinence; Patent A290/99 Implantable incontinence device
Expert Testimony - GBA Pharma
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; CureVac; Ferring; Ipsen; Janssen; Sanofi/Aventis